American studies have found a new cosmetic drug, Aquamid, to be effective in the treatment of HIV-related lipoatrophy.
A four-year study into the use of Aquamid, reported in this month’s AIDS Research and Human Retroviruses journal, has shown it to be a safe treatment for facial wasting caused by some HIV drugs.
Of 145 patients who received the treatment, 89 percent reported feeling satisfied or very satisfied with the results after four years. Nineteen percent reported the development of small nodules after treatment.
There are currently no plans to trial the treatment in Australia, although Positive Life spokesman Rob Lake said there were new possibilities for listing Sculptra on the Pharmaceutical Benefits Scheme.
Turned down for listing at the end of last year, Sculptra is once again being considered by the PBS.
We’re awaiting the Pharmaceutical Benefits Advisory Committee’s decision. We’re hoping it will happen soon, but it takes time, Lake told Sydney Star Observer.
There has to be a number of flow-on decisions considered around how it’s going to be made available and pricing and things like that, but we’re hoping it will happen in the next couple of months.